Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;6 // 2. Cornford P, Bellmunt J, Bolla M, Briers E, de Santis M, Gross T, et al. EAU-ESTRO SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur Urol 2017;71:630-42.
DOI: 10.1016/j.eururo.2016.08.002
Cabrera-Martín MN, Ortega-Candil A, Carreras-Delgado JL. PET y radionúclidos en cáncer de próstata. Rev Cancer 2016;30:9-18.
Pelosi E, Arena V, Skanjeti A, Pirro V, Douroukas A, Pupi A, et al. Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer. Radiol Med 2008;113:895-904.
DOI: 10.1007/s11547-008-0263-8
Cornford P, Bellmunt J, Bolla M, Briers E, de Santis M, Gross T, et al. EAU-ESTRO SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur Urol 2017;71:630-42.
DOI: 10.1016/j.eururo.2016.08.002
Fanti S, Nanni C, Ambrosini V, Gross MD, Rubello D, Farsad M. PET in genitourinary tract cancers. Q J Nucl Med Mol Imaging 2007;51(3):260-71.
Effert PJ, Bares R, Handt S, Wolf JM, Bull U, Jakse G. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J Urol 1996;155:994-8.
DOI: 10.1016/S0022-5347(01)66366-3
Öztürk H, Karapolat I. 18F-fluorodeoxyglucose PET/CT for detection of disease in patients with prostate-specific antigen relapse following radical treatment of a local-stage prostate cancer. Oncol Lett 2016;11:316-22.
DOI: 10.3892/ol.2015.3903
Roivainen A, Forsback S, Gronroos T, Lehikoinen P, Kähkönen M, Sutinen E, et al. Blood metabolism of [methyl-11C]choline; implications for in vivo imaging with positron emission tomography. Eur J Nucl Med 2000;27:25-32.
DOI: 10.1007/PL00006658
Castellucci P, Fuccio C, Nanni C, Santi I, Rizzello A, Lodi F, et al. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med 2009;50:1394-400.
DOI: 10.2967/jnumed.108.061507
Von Eyben FE, Kairemo K. Meta-analysis of 11C-choline and 18F-choline PET/CT for management of patients with prostate cancer. Nucl Med Commun. 2014 Mar;35(3):221-30.
DOI: 10.1097/MNM.0000000000000040
Hara T, Kosaka N, Shinoura N, Kondo T. PET imaging of brain tumor with [methyl-11C-choline. J Nucl Med 1997;38:842-7.
Picchio M, Landoni C, Messa C, Gianolli L, Matarrese M, De Cobelli F, et al. Positive [11C]choline and negative [18F]FDG with positron emission tomography in recurrence of prostate cancer. AJR Am J Roentgenol 2002;179:482-4.
DOI: 10.2214/ajr.179.2.1790482
Müller SA, Holzapfel K, Seidl C, Treiber U, Krause BJ, Sene kowitsch-Schmidtke R. Characterization of choline uptake in prostate cancer cells following bicalutamide and docetaxel treat ment. Eur J Nucl Med Mol Imaging 2009;36:1434-42.
DOI: 10.1007/s00259-009-1117-x
Picchio M, Crivellaro C, Giovacchini G, Gianolli L, Messa C. PET-CT for treatment planning in prostate cancer. Q J Nucl Med Mol Imag 2009; 53(2):245-68.
Cimitran M, Bortolus R, Morassut S, Canzonieri V, Garbeglio A, Baresic T, et al. [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 2006;33:1387-98.
DOI: 10.1007/s00259-006-0150-2
Roivainen A, Parkkola R, Yli-Kerttula T, Lehikoinen P, Viljanen T, Möttönen T et al. Use of positron emission tomography with methyl-11C-choline and 2-18F-fluoro-2- deoxy-D-glucose in comparison with magnetic resonance imaging for the assessment of inflammatory proliferation of synovium. Arthritis Rheum 2003; 48:3077-84.
DOI: 10.1002/art.11282
Schillaci O, Calabria F, Tavolozza M, Ciccio C, Carlani M, Caracciolo CR, et al. 18F choline PET/CT physiological distribution and pitfalls in image interpretation: experience in 80 patients with prostate cancer. Nucl Med Commun 2010;31:39-45.
DOI: 10.1097/MNM.0b013e328330adc5
Yoshimoto M, Waki A, Yonekura Y, Sadato N, Murata T, Omata N, et al. Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl Med Biol 2001;28:117-22.
DOI: 10.1016/S0969-8051(00)00195-5
Swinnen JV, Van Veldhoven PP, Timmermans L, De Schrijver E, Brusselmans K, Vanderhoydonc F, et al. Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains. Biochem Biophys Res Commun 2003;302:898-903.
DOI: 10.1016/S0006-291X(03)00265-1
Kato T, Tsukamoto E, Kuge Y, Takei T, Shiga T, Shinohara N, et al. Accumulation of [11C]acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer. Eur J Nucl Med Mol Imaging 2002;29:1492-5.
DOI: 10.1007/s00259-002-0885-3
Núñez R, Macapinlac HA, Yeung HW, Akhurst T, Cai S, Osman I, et al. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med 2002;43:46-55.
Schuster DM, Votaw JR, Nieh PT, Yu W, Nye JA, Master V, et al. Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med 2007;48:56-63.
Ischia J, Patel O, Bolton D, Shulkes A, Baldwin GS. Expression and function of gastrin-releasing peptide (GRP) in normal and cancerous urological tissues. BJU Int 2014;113 Suppl 2:40-7.
DOI: 10.1111/bju.12594
Koo PJ, Kwak JJ, Pokharel S, Choyke PL. Novel imaging of prostate cancer with MRI, MRI/US, and PET. Curr Oncol Rep 2015;17:56.
DOI: 10.1007/s11912-015-0480-y
Eiber M, Fendler WP, Rowe SP, Calais J, Hofman MS, Maurer T, et al. Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy. J Nucl Med 2017;58:67S-76S.
DOI: 10.2967/jnumed.116.186767
Derlin T, Weiberg D, Von Klot C, Wester HJ, Henkenberens C, Ross TL, et al. 68Ga-PSMA I&T PET/CT for assessment of prostate cancer: evaluation of image quality after forced diuresis and delayed imaging. Eur Radiol 2016;26:4345-53.
DOI: 10.1007/s00330-016-4308-4
Werner RA, Derlin T, Lapa C, Sheikbahaei S, Higuchi T, Giesel FL, et al. 18F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging. Theranostics 2020;10(1):1-16.
DOI: 10.7150/thno.37894
Oprea-Lager D. Piflufolastat (18F)PET/CT: the Nuclear Medicine Physician´s perspective. EANM 2023.
Kirienko M, Sollini M, Lopci E, Versari A, Chiti A. Applications of PET imaging with radiolabelled choline (11C/18F-choline). Q J Nucl Med Mol Imaging 2015;59:83-94.
Picchio M, Giovanninia E, Messa C. The role of PET/computed tomography scan in the management of prostate cancer. Curr Opin Urol 2011;21:230-6.
DOI: 10.1097/MOU.0b013e328344e556
Farsad M, Schiavina R, Castellucci P, Nanni C, Corti B, Martorana G, et al. Detection and localization of prostate cancer: correlation of 11C-choline PET/CT with histopathologic step-section analysis. J Nucl Med 2005;46:1642-9.
Giovacchini G, Picchio M, Coradeschi E, Scattoni V, Bettinardi V, Cozzarini C, et al. [11C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and antiandrogenic therapy. Eur J Nucl Med Mol Imaging 2008;35:1065-73.
DOI: 10.1007/s00259-008-0716-2
Emmett L, Papa N, Buteau J, Ho B, Roberts M, Thompson J, et al. The PRIMARY Score: using intraprostatic 68Ga-PSMA PET/CT patterns to optimize prostate cancer diagnosis. J Nucl Med 2022;63:1644-50.
Emmett L, Buteau J, Papa N, Moon D, Thompson J, Roberts MJ, et al. The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetis resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentric study. Eur Urol 2021;80:682-9.
DOI: 10.1016/j.eururo.2021.08.002
Beheshti M, Imamovic L, Broinger G, Vali R, Waldenberger P, Stoiber F, et al. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology 2010;254(3):925-33.
DOI: 10.1148/radiol.09090413
Virgolini I, Decristoforo C, Haug A, Fanti S, Uprimny C, et al. Current status of theranostics in prostate cancer. Eur J Nucl Med Mol Imaging 2018;45(3):471-95.
DOI: 10.1007/s00259-017-3882-2
Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 2020;395(10231):1208-16.
DOI: 10.1016/S0140-6736(20)30314-7
Pienta KJ, Gorin MA, Rowe SP, Carroll PR, Pouliot F, Probst S, et al. A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY). J Urol 2021;206(1):52-61.
DOI: 10.1097/JU.0000000000001698
Jansen BHE, Bodar YJL, Zwezerrijnen GJC, Meijer D, Van der Voorn JP, et al. Pelvis lymph-node staging with 18F-DCFPyL PET/CT prior to extended pelvis lymph node dissection in primary prostate cancer-the SALT trial- Eur J Nucl Med Mol Imaging 2021;48:509-20.
DOI: 10.1007/s00259-020-04974-w
Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M, et al. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT. J Nucl Med 2018;59(3):469-78.
DOI: 10.2967/jnumed.117.198119
Ceci F, Oprea-Lager DE, Emmett L, Adam JA, Bomanji J, Czernin J, et al. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. Eur J Nucl Med Mol Imaging 2021;48(5):1626-38.
DOI: 10.1007/s00259-021-05245-y
Seifert R, Emmett L, Rowe SP, Herrmann K, Hadaschik B, Calais J, et al. Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2). Eur Urol 2023;83(5):405-12.
DOI: 10.1016/j.eururo.2023.02.002
Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, et al. Prospective comparison of 18F-Fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med 2015;56:1185.
DOI: 10.2967/jnumed.115.160382
Afshar-Oromieh A, Haberkorn U, Schlemmer HP, Fenchel M, Eder M, Eisenhut M, et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2014;41:11.
DOI: 10.1007/s00259-013-2525-5
Caroli P, Sandler I, Matteucci F, De Giorgi U, Uccelli L, Celli M, et al. 68Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients. Eur J Nucl Med Mol Imaging 2018;45:2035.
DOI: 10.1007/s00259-018-4067-3
Morris MJ, Rowe SP, Gorin MA, Saperstein L, Pouliot F, Josephson D, et al. Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study. Clin Cancer Res 2021;27(13):3674-82.
DOI: 10.1158/1078-0432.CCR-20-4573
Oprea-Lager DE, Gontier E, García-Cañamaque L, Gauthé M, Olivier P, Mitjavila M, et al. [18F]DCFPyL PET/CT versus [18F]fluoromethylcholine PET/CT in Biochemical Recurrence of Prostate Cancer (PYTHON): a prospective, open label, cross-over, comparative study. Eur J Nucl Med Mol Imaging 2023;50:3439-51.
DOI: 10.1007/s00259-023-06301-5
Mottet N, Cornford P, Van den Bergh RCN, Briers E, Eberli D, De Meerleer G, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. European Association of Urology 2023.
Gafita A, Rauscher I, Weber I, Hadaschik B, Wang H, Wesley R, et al. Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study. J Nucl Med 2022;63:1651-8.
DOI: 10.1055/s-0042-1745946
Fankhauser CD, Poyet C, Kroeze SGC, Kranzbühler B, Schüler HIG, Guckenberger M, et al. Current and potential future role of PSMA-PET in patients with castration-resistant prostate cáncer. World J Urol 2019;37:457-67.
DOI: 10.1007/s00345-018-2408-2
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med 2019;380:1235-46.
DOI: 10.1056/NEJMoa1815671
Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, et al. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med 2018;378:2465-74.
DOI: 10.1056/NEJMoa1800536
Fendler WP, Weber M, Iravani A, Hofman MS, Calais J, Czernin J, et al. Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer. Clin Cancer Res 2019;25:7448-54.
DOI: 10.1158/1078-0432.CCR-19-1050
Farolfi A, Calderoni L, Mattana F, Mei R, Telo S, Fanti S, Castellucci P. Current and Emerging Clinical Applications of PSMA PET Diagnostic Imaging for Prostate Cancer. J Nucl Med 2021;10(62):596-604.
DOI: 10.2967/jnumed.120.257238
Onal C, Ozyigit G, Oymak E, Guler OC, Tilki B, Hurmuz P, Akyol F. Stereotactic radiotherapy to oligoprogressive lesions detected with 68Ga-PSMA-PET/CT in castration-resistant prostate cancer patients. Eur J Nucl Med Mol Imaging 2021;48:3683-92.
DOI: 10.1007/s00259-021-05298-z
Kalinauskaite G, Senger C, Kluge A, Furth C, Kufeld M, Tinhofer I, et al. 68Ga-PSMA-PET/CT-based radiosurgery and stereotactic body radiotherapy for oligometastatic prostate cáncer. PLoS One 2020;15:e0240892.
DOI: 10.1371/journal.pone.0240892
Rogowski P, Roach M 3rd, Schmidt-Hegemann NS, Trapp C, von Bestenbostel R, Shi R, et al. Radiotherapy of oligometastatic prostate cancer: a systematic review. Radiat Oncol 2021;16:50.
DOI: 10.1186/s13014-021-01776-8
Número de descargas:
24835
Número de visitas:
1138
Citas:
0
